¸¸¼ºÄáÆϺ´ ¹Ì³×¶ö-»ÀÁúȯ ¿¬±¸È¸ CKD-MBD ¿¬±¸È¸ ¿¬¼ö°Á : 2023-09-10
±³À°ÀÏÀÚ : 2023-09-10
±³À°Àå¼Ò : ¼¿ï/°í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò ±³À°°ü 1Ãþ ´ë°´ç
±³À°ÁÖÁ¦ : CKD-MBD ¿¬±¸È¸ ¿¬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼ºÄáÆϺ´ ¹Ì³×¶ö-»ÀÁúȯ ¿¬±¸È¸
´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ : ksn@ksn.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 250¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í Àü¹®ÀÇ 3¸¸¿ø, ÀüÀÓÀÇ ¹× Àü°øÀÇ 2¸¸¿ø, °£È£»ç 1¸¸¿ø, ´çÀϵî·Ï : Àü¹®ÀÇ 4¸¸¿ø, ±×¿Ü 3¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 08:30~09:00 Parathyroid gland in Health °µ¿Çõ(ºÎõ ¼º¸ðº´¿ø)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 09:00~09:20 Parathyroid cell proliferation in Disease; Primary vs. Secondary Á¤°æõ(¼¿ï´ëº´¿ø º´¸®°ú)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 09:20~09:50 Consequences of Hyperparathyroidism - mineral, bone, extra skeletal Á¤Áö¿ë(°¡Ãµ±æº´¿ø)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 09:50~10:20 Differential diagnosis in Primary hyperparathyroidism in CKD Á¶¾ÆÁø(ÇѸ²´ë °³²¼º½Éº´¿ø)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 10:20~10:50 Imaging for Hyperparathyroidism; Primary vs. Secondary ÃÖÇýÁ¤(ºÐ´çÂ÷º´¿ø ¿µ»óÀÇÇаú )
ÈÞ½Ä 09¿ù 10ÀÏ ´ë°´ç 10:50~11:10 Break ()
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 11:10~11:35 Additive beneficial effects of GLP-1 agonist in CKD [IV & oral] ±èÁ°æ(ÆòÃÌ ÇѸ²´ëº´¿ø)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 11:35~12:00 Additive beneficial effects of mineralocorticoid receptor antagonist in CKD ÃÖÀ¯Á¤(°í´ë±¸·Îº´¿ø ¼øȯ±â)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 12:00~12:20 Primary hyperparathyroidism Guideline 2022 È«¾Æ¶÷(ȼøÀü³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 12:20~12:50 Surgery vs. Radiofrequency Ablation ±è¿ì¿µ(°í´ë±¸·Îº´¿ø)
±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°´ç 12:50~13:30 VDRAs, Cinacalcet, Evocalcet, Etelcalcetide & Upacicalcet in Secondary hyperparathyroidism ¾È½Å¿µ(°í´ë±¸·Îº´¿ø)